tiprankstipranks
Analyst Profile
Followed by 11 other investors
.
Drew Ranieri

Drew Ranieri

Morgan Stanley
Wall Street Analyst
Ranked #6,898 out of 7,991 Analysts on TipRanks (#18,607 out of 21,404 overall experts)

Success Rate

41%
24 out of 58 Profitable Transactions

Average Return

-5.50%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied Drew Ranieri's ratings since 2021 and opened each position for the duration of 1 Year:
41.38% of your transactions would have been profitable with an average return of -5.5%

Stock Rating Distribution

110Ratings
50.00% Buy
42.73% Hold
7.27% Sell
Distribution of Drew Ranieri's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
Neuropace, Inc.
(NPCE)
Rating Type:Sell
Dates:Jan 07, 2022 - Jan 01, 1970
Gain:46.70%
The most profitable rating made by Drew Ranieri

Drew Ranieri's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
Hill-Rom
Hold
Downgraded
100%
+8.70%
3
Zimmer Biomet Holdings
Hold
Reiterated
0%
-14.90%
7
Bioventus
Buy
Reiterated
$11.00
(27.02% Upside)
33%
-27.43%
4
Stevanato Group
Buy
Reiterated
$19.00
(5.67% Upside)
67%
+1.77%
4
Haemonetics
Hold
Reiterated
$70.00
(-4.89% Downside)
0.00%
7
Stryker
Hold
Reiterated
$220.00
(0.36% Upside)
75%
+0.45%
8
NeuroPace
Sell
Reiterated
$5.50
(-3.17% Downside)
60%
+4.14%
6
Agiliti
Buy
Reiterated
$25.00
(46.71% Upside)
43%
-2.54%
7
Avanos Medical
Sell
Reiterated
$28.00
(-0.74% Downside)
80%
+6.74%
5
NuVasive
Hold
Reiterated
$54.00
(5.12% Upside)
0.00%
6
List of latest recommendations made by Drew Ranieri. Click to expand and see Drew Ranieri's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More